Ben Scruggs is a Partner at Hatteras, where he focuses on biotechnology and life science tools companies. He has experience building and scaling healthcare companies across therapeutic areas including inflammation, oncology, neurodegeneration, ophthalmology, cell therapy, and gene therapy.
Ben serves as CEO and Chairman of Altis Biosystems and has held leadership roles at Tune Therapeutics and L2 Ventures. He also serves on the boards of IMMvention Therapeutix and Veralox Therapeutics, and has previously supported multiple acquired biotech companies as a board observer.
He earned his Ph.D. in Molecular Cell Biology from Washington University in St. Louis and a B.E. in Biomedical Engineering from Vanderbilt University. Ben is active in professional advisory roles, including the Crohn’s and Colitis Foundation Corporate Advisory Group and Vanderbilt University School of Engineering’s Council of Advisors.
